GLP-1 Insurance Coverage at the 10 Largest US Insurers: A 2026 Audit

Weight Loss Rankings tracks GLP-1 weight loss coverage across the 10 largest US health insurers, which together cover approximately 464M American members. The audit reveals a pattern that's as consistent as it is frustrating: every single insurer in our index covers GLP-1 medications under at least some plans, every single one requires prior authorization, and not one of them offers consistent plan-wide approval. This is what “varies by plan” actually means in practice — and it's why so many patients pivot to compounded alternatives instead of fighting through the prior auth maze.

The headline numbers from our audit

10 of 10 insurers in our index require prior authorization for at least one FDA-approved GLP-1 weight loss drug. That's 100% of the major US health insurance market. Prior authorization means your prescriber must submit clinical documentation (typically a documented BMI ≥ 30, or BMI ≥ 27 with comorbidities, plus failure of prior weight loss attempts) and wait for the insurer's pharmacy benefit manager to approve the prescription before it can be filled. Approval rates vary widely by plan and by specific drug.

Insurer-by-insurer coverage breakdown

Below is the full audit, sorted by member count (largest first). Each insurer links to our individual coverage page with details on their specific GLP-1 drug formulary, prior auth criteria, and member-reported approval rates.

What “varies by plan” actually means in practice

Most of the insurers in our audit answer “does your plan cover Wegovy?” with some version of “it depends on your specific plan, your employer's formulary choices, and your prior auth determination.” That sounds reasonable until you realize what it means in practice: a single insurer can offer thousands of distinct plans, and the GLP-1 formulary status varies across them based on factors completely outside the patient's control:

• Employer-funded vs fully insured. If your coverage comes through a large self-insured employer plan (most Fortune 500 companies), the formulary is set by your employer's HR/benefits team in consultation with the PBM, not by the insurer brand on your card.
• Indication restriction. Many plans cover semaglutide as Ozempic for type 2 diabetes (where the cost basis is established and the FDA indication is clear) but exclude or heavily restrict semaglutide as Wegovy for weight loss alone. Same drug, same molecule, two different formulary statuses depending on which trade name your prescription is written for.
• Step therapy. Your prior auth may require documented failure of cheaper alternatives first (phentermine, orlistat, liraglutide) before the insurer will approve semaglutide or tirzepatide. The step therapy requirements vary by insurer and by plan.
• Quantity limits. Some plans approve the starting 0.25mg or 2.5mg dose for the first three months but require re-authorization to escalate to the maintenance dose, even after the patient has tolerated the medication.
• Annual reauthorization. Many plans require full prior auth re-submission every 12 months, with renewed documentation of weight loss progress, BMI, and continued medical necessity.

The compounded alternative when prior auth fails

Patients who get denied — or who can't face the prior auth process — increasingly pivot to compounded GLP-1 telehealth providers, which sell the same active molecule (semaglutide or tirzepatide) at cash-pay prices below most insurance copays. Our GLP-1 pricing index tracks the current market median across 80+ telehealth providers, and our cheapest compounded semaglutide investigation documents the floor-price providers we've verified.

For most patients, the actual decision tree looks like this:

1. Try insurance first. If your insurance covers Wegovy or Zepbound at a copay below ~$200/month, that's almost always the right answer. Brand-name drugs with insurance beat compounded out-of-pocket.
2. If denied, appeal once. Most insurers have a one-page appeal process. About a third of denials are reversed on appeal when the prescriber attaches documentation of BMI, comorbidities, and prior weight loss attempts.
3. If still denied, switch to compounded. The cash-pay floor is roughly half what most insurance copays would be even for an approved prescription. Use our savings calculator to see your specific number.

Why this article updates automatically

Every number above — total member count, coverage status distribution, prior auth percentage, the per-insurer table — is computed at render time from our editorial insurance dataset in src/data/insurers.json. When an insurer changes their formulary, when we add a new insurer to the audit, or when the underlying coverage status shifts, the article reflects the update on the next deploy with no manual editing.

For details on a specific insurer, follow the links in the table above to our per-insurer coverage pages. For the broader editorial methodology, see our methodology page.